Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Yukuan Feng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-6497-0748; OpenAlex author ID A5027275948. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2024: 1 paper · 2025: 5 papers · 2026: 6 papers

Papers 12

  1. Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Co-author DOI 10.1002/advs.202509074↗
  2. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  3. Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy. Co-author DOI 10.1038/s42003-026-09770-0↗
  4. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  5. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Co-author DOI 10.1136/gutjnl-2025-336277↗
  6. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  7. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  8. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  9. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  10. Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation. Last author DOI 10.1186/s13046-025-03409-4↗
  11. GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2025.0040↗
  12. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 10 shared papers, 2024–2026 · strength 2.10
  2. Chongbiao Huang · 7 shared papers, 2024–2026 · strength 1.40
  3. Tianxing Zhou · 6 shared papers, 2025–2026 · strength 1.31
  4. Yongjie Xie · 6 shared papers, 2025–2026 · strength 1.23
  5. Xiuchao Wang · 6 shared papers, 2024–2026 · strength 1.16
  6. Tiansuo Zhao · 6 shared papers, 2024–2026 · strength 1.16
  7. Chao Yang · 5 shared papers, 2025–2026 · strength 1.06
  8. Jun Yu · 5 shared papers, 2025–2026 · strength 1.03
  9. Song Gao · 5 shared papers, 2024–2026 · strength 0.96
  10. Qingxiao Fang · 4 shared papers, 2025–2026 · strength 0.85
  11. Yifei Wang · 3 shared papers, 2026 · strength 0.67
  12. Shangheng Shi · 3 shared papers, 2026 · strength 0.62
  13. Jing Liu · 3 shared papers, 2024–2026 · strength 0.62
  14. Chao Xu · 2 shared papers, 2024–2026 · strength 0.42
  15. Hui Li · 2 shared papers, 2024–2026 · strength 0.42
  16. Peng Xie · 2 shared papers, 2024–2026 · strength 0.42
  17. Huizhi Sun · 2 shared papers, 2024–2026 · strength 0.42
  18. Yiping Zou · 2 shared papers, 2025 · strength 0.37
  19. Shengyu Yang · 2 shared papers, 2024–2026 · strength 0.37
  20. Qing Xia · 1 shared paper, 2025 · strength 0.26
  21. Yuli Lin · 1 shared paper, 2025 · strength 0.26
  22. Tianyi Zhu · 1 shared paper, 2025 · strength 0.26
  23. Wei Lin · 1 shared paper, 2026 · strength 0.25
  24. Zhi Ji · 1 shared paper, 2026 · strength 0.20
  25. Rui Liu · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.